Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care.

CLINICAL TRIAL - BREAST CANCER



Phase: Phase III

Cancer Category: Breast

Principal Investigator: Jailan Elayoubi, M.D.

Karmanos Trial ID: S2206

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Chemotherapy, Immunotherapy

Eligibility Criteria

• ER+/PR+/HER2- breast cancer, clinical stages II or III
• MammaPrint High Risk 2 result (testing provided during screening)
• No prior treatments; must be candidate for doxorubicin, paclitaxel, and durvalumab therapy
• ECOG 0-2

Refer a Patient

CLINICAL TRIAL - PANCREATIC

Phase: Phase II

Cancer Category: Gastrointestinal (GI)

Principal Investigator: Anthony Shields, M.D., Ph.D.

Karmanos Trial ID: 2023-104

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Chemotherapy

Devices: TheraBionic P1 device

Eligibility Criteria

• Metastatic pancreatic adenocarcinoma
• Measurable disease per RECIST 1.1
• No gemcitabine/paclitaxel within 6 months of study entry

Refer a Patient

CLINICAL TRIAL - MELANOMA

Phase: Phase III

Principal Investigator: Yusra Shao, M.D.

Karmanos Trial ID: 2023-044

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Biological Therapy, Immunotherapy

Eligibility Criteria

• Previously untreated, unresectable stage III or stage IV melanoma
• Known BRAF status (may submit tissue for testing if unknown)
• Measurable disease per RECIST 1.1

Refer a Patient

CLINICAL TRIAL -

NON-SMALL CELL LUNG CANCER

Phase: Phase III

Principal Investigator: Dipesh Uprety, M.D.

Karmanos Trial ID: 2023-101

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

Therapies: Biological Therapy, Chemotherapy, Immunotherapy

Eligibility Criteria

• Newly diagnosed locally advanced or metastatic non-small cell lung cancer
• KRAS G12c-mutant
• Known PD-L1 status

Refer a Patient

GYNECOLOGIC 

Applicable Disease Sites: Cervix; Other Female Genital; Ovary

Principal Investigator: Ira Winer, M.D., Ph.D., FACOG

Karmanos Trial ID: 2023-102

Age Group: Adults

Locations Available:

• Karmanos Cancer Institute - Detroit
• Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills
• Wayne State University

Eligibility Criteria

• Biopsy-confirmed gynecologic cancer or have imaging/laboratory findings highly concerning for a cancer diagnosis
• Has not yet seen a Gyn Onc
• Understands spoken and written English

Refer a Patient